This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients | MicrobiomeTrials
← Back to trials NCT06306014
Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients Recruiting PHASE1, PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2024-05-07Est. Completion: 2028-01-07
Enrollment target: 56 participantsLocations CH Annecy Genevois Service de Maladies infectieuses, Annecy, France Service d'hépato-gastroentérologie - CHU Estaing, Clermont-Ferrand, France CHU Grenoble Service Maladies infectieuses et tropicales, Grenoble, France CHU Lille Unité des Maladies Infectieuses et tropicales, Lille, France Service d'Hépato-gastroentérologie Hôpital de la Croix Rousse, Lyon, France APHM La Timone Service de Maladies infectieuses, Marseille, France Service d'hépato-gastroentérologie - Hôpital Saint Antoine (APHP), Paris, France Service d'infectiologie - Hôpital Nord / CHU Saint Etienne, Saint-Etienne, France Service de médecine interne - Pôle des maladies de l'appareil digestif - CHU de Toulouse, Toulouse, France Service de Maladies Infectieuses - CH de Valence, Valence, France Other microbiome trials you might be interested in Hemodialysis
The purpose of this study is to assess the efficacy of prophylactic antibiotic treatment on blood stream infections and …
Copenhagen, Denmark Est. completion Oct 2028
Leukemia, Lymphocytic, Acute Leukemia, Myeloid, Acute Lymphoma Clostridium Difficile Infection Solid Cancers
The primary objective of the study is to determine whether dietary intervention to increase fiber and decrease fat reduc…
Aurora, United States Completed Jul 2, 2025
Clostridioides Difficile Infection
The purpose of this study is to evaluate the efficacy and safety of AZD5148 for prevention of recurrence of Clostridioid…
Phoenix, United States Est. completion Apr 20, 2027